Valuation: Taho Pharmaceuticals Ltd.

Market Cap 11.53B 363M 324M 302M 275M 517M 34.98B 521M 3.65B 1.42B 17.85B 1.36B 1.33B 57.38B P/E 2024
-12x
P/E 2025 -26.8x
Enterprise Value 11.15B 351M 313M 292M 266M 500M 33.83B 504M 3.53B 1.37B 17.26B 1.32B 1.29B 55.49B EV / Sales 2024
-
EV / Sales 2025 636x
Free-Float
84.77%
Yield 2024 *
-
Yield 2025 -
1 day-4.76%
1 week-6.38%
Current month-8.71%
1 month+13.11%
3 months+102.76%
6 months+75.30%
Current year+97.31%
1 week 219
Extreme 219
250.5
1 month 192.5
Extreme 192.5
302
Current year 100.5
Extreme 100.5
302
1 year 100.5
Extreme 100.5
302
3 years 32.25
Extreme 32.25
302
5 years 32.25
Extreme 32.25
302
10 years 1.9
Extreme 1.9
302
Manager TitleAgeSince
Chief Executive Officer 64 2014-03-09
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member - -
Chairman 64 2014-03-09
Director/Board Member 61 2014-03-26
Change 5-day change 1-year change 3-year change Capi.($)
-4.76%-6.38%+30.56%+9,465.22% 363M
+0.02%-3.52%+36.11%+111.11% 1,019B
-1.21%-6.99%+34.08%+60.96% 610B
+1.12%-0.20%+13.62%+80.24% 470B
-3.30%-6.15%+56.45%+34.69% 344B
+1.10%+1.32%+22.71%+42.64% 336B
+0.97%-2.45%+11.49%+33.47% 266B
+2.16%-2.91%-5.19%+10.27% 241B
-0.01%-3.62%+35.28%+52.02% 218B
-0.08%-4.98%+28.34%+93.61% 179B
Average +0.28%-4.15%+26.35%+998.42% 368.32B
Weighted average by Cap. +0.93%-3.51%+28.67%+69.85%

Financials

2024 2025
Net sales - 8.41M 265K 236K 220K 200K 377K 25.51M 380K 2.66M 1.04M 13.02M 994K 973K 41.85M
Net income -167M -5.27M -4.7M -4.38M -3.99M -7.51M -508M -7.57M -52.96M -20.61M -259M -19.8M -19.37M -833M -214M -6.75M -6.02M -5.61M -5.11M -9.62M -650M -9.69M -67.82M -26.39M -332M -25.35M -24.8M -1.07B
Net Debt -479M -15.09M -13.47M -12.55M -11.42M -21.5M -1.45B -21.66M -152M -58.98M -742M -56.66M -55.44M -2.38B -379M -11.93M -10.64M -9.91M -9.02M -16.99M -1.15B -17.11M -120M -46.6M -586M -44.77M -43.81M -1.88B
Logo Taho Pharmaceuticals Ltd.
Taho Pharmaceuticals Ltd a Taiwan-based company that mainly develops Transepithelial Delivery System (TDS) drug delivery technology. The Company absorbs small molecule drugs through the skin or transmucosal absorption, and the dosage forms include transdermal absorption patches, oral dissolving films and buccal dissolving films. The drugs include five major areas, including drugs for cardiovascular diseases, opium addiction withdrawal and overdose emergency drugs, cancer care, central nervous system drugs, and respiratory diseases. In addition to developing new dosage forms of drugs on its own, the Company also accepts commissions from major pharmaceutical companies or biotech companies to develop new dosage forms of products. New drugs under development include the TAH3311 orodispersible film and TAH3341 orodispersible film, TAH2231 buccal-dispersible film, generic drugs include TAH4411 orodispersible film, TAH9922 oral solution, the TAH2211 sublingual orodispersible film and others.
Employees
35
Date Price Change Volume
26-10-05 NT$220.00 -4.76% 849,580
26-10-02 NT$231.00 +0.43% 571,009
26-10-01 NT$230.00 -4.56% 1,050,070
26-09-30 NT$241.00 -0.21% 599,035
  1. Stock Market
  2. Stocks
  3. 6467 Stock